Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
Authors
Keywords
-
Journal
ANNALS OF HEMATOLOGY
Volume 100, Issue 10, Pages 2541-2546
Publisher
Springer Science and Business Media LLC
Online
2021-07-26
DOI
10.1007/s00277-021-04594-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy.
- (2020) Gordon Cook et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
- (2020) Chenguang Shen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
- (2020) Evangelos Terpos et al. LEUKEMIA
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating the burden of SARS-CoV-2 in France
- (2020) Henrik Salje et al. SCIENCE
- COVID-19 in Immunocompromised Hosts: What We Know So Far
- (2020) Monica Fung et al. CLINICAL INFECTIOUS DISEASES
- Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
- (2020) Katharina Helene Susek et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
- (2020) Bo Wang et al. Journal of Hematology & Oncology
- Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
- (2020) Joaquín Martínez-López et al. Blood Cancer Journal
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
- (2020) Abi Vijenthira et al. BLOOD
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
- (2020) Ajai Chari et al. BLOOD
- Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies
- (2018) Min Chen et al. ANNALS OF HEMATOLOGY
- Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
- (2018) Jennifer L. J. Heaney et al. LEUKEMIA
- Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study
- (2018) Rasmus Sørrig et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
- (2017) Rasmus Sørrig et al. PLoS One
- Multiple myeloma epidemiology and survival: A unique malignancy
- (2016) Dickran Kazandjian SEMINARS IN ONCOLOGY
- Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection
- (2014) Benjamin W. Teh et al. BLOOD REVIEWS
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
- (2014) C. Blimark et al. HAEMATOLOGICA
- The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
- (2009) M. Basler et al. JOURNAL OF IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started